AIM
IPXL

Acrospire Investment Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Acrospire Investment Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,875
Closed -$171K – 2666
2016
Q4 		$171K Buy
+12,875
New +$220K 0.07% 480
2016
Q3 		– Sell
-3,910
Closed -$113K – 2298
2016
Q2 		$113K Buy
3,910
+2,600
+198% +$84.7K 0.08% 352
2016
Q1 		$42K Buy
+1,310
New +$46.1K 0.03% 1107

Other funds holding IPXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Acrospire Investment Management's IPXL Position: Q1 2017 in Review

Acrospire Investment Management sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 12,875 shares — an estimated $171K sold.

Acrospire Investment Management first reported a position in IPXL in Q1 2016 and held it in 3 quarters. The position peaked at $171K in Q4 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • Acrospire Investment Management reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 12,875 Impax Laboratories, Inc. shares in Q1 2017, an estimated $171K.
  • Acrospire Investment Management first reported a position in Impax Laboratories, Inc. in Q1 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Impax Laboratories, Inc. position peaked at $171K in Q4 2016.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Acrospire Investment Management's 13F filing for Q1 2017, filed 4 May 2017.